|
Feb 17
|
When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)?
|
|
Jan 10
|
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
|
|
Nov 15
|
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
|
|
Nov 8
|
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
|